Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

A closer look at Urovant’s vibegron blood pressure study

By Brian Buntz | September 15, 2021

UrovantIn recent years, regulators including FDA have increased their focus on the potential of drugs to cause blood pressure increases. To that end, the agency asked Urovant (Irvine, California) to study the impact of the beta-3 adrenergic receptor agonist vibegron on blood pressure.

The study, recently published in the Journal of Urology, found no significant change in blood pressure among either vibegron or placebo recipients. There were 96 patients in the vibegron group. Another 101 received placebo. “The good news was that the changes in blood pressure were trivial — on average less than one millimeter of mercury,” said Dr. Michael A. Weber, a professor of medicine at SUNY Downstate College of Medicine in New York, who was involved in the study. 

Weber recently summarized the results at the Annual Meeting of the American Urological Association. 

FDA approved vibegron in late 2020. In addition, the agency approved another beta-3 adrenergic receptor agonist known as mirabegron from Astellas Pharma in 2012. “There was some concern with early studies of mirabegron that it might be raising blood pressure,” said Weber. The reason being is that beta receptors are found in the heart and blood vessels and could potentially influence blood pressure. 

But vibegron, along with mirabegron, are beta-3 drugs. So while beta-1 and beta-2 drugs could affect blood pressure, beta-3 drugs are “probably going to be neutral,” Weber reasoned. 

While the label for mirabegron mentions the possible increase in blood pressure, “it’s turned out not to be very much of a problem,” Weber said. 

But when vibegron came along, the agency recommended doing “a careful clinical trial to show you don’t have an adverse blood pressure effect,” Weber continued.  

The trial measured ambulatory blood pressure multiple times per hour throughout the day. “If you just simply average them out, you get a very strong representative value for a patient’s whole-day blood pressure,” Weber said. “The FDA loves that because, now, you can look at a new drug and quantify very precisely whether there was a change.” 

The researchers also crawled through the data to see if any individual patients appeared to have dangerous changes in blood pressure over the four-week trial period. Again, they could not find outliers compared with just placebo recipients. “It was a second reassurance that everything was okay,” Weber said. 


Filed Under: Cardiovascular, Urology
Tagged With: beta-3 adrenergic receptor, blood pressure, FDA, hypertension, Journal of Urology, Michael A. Weber, mirabegron, Urovant
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Sanofi ramps up distribution of Beyfortus ahead of RSV season
BMS
Label update broadens Camzyos reach in obstructive HCM, trims echo burden for stable patients
FDA logo
FDA drug approvals holding steady at 44 YTD in 2024
DNA double helix transforming into bar graphs, blue and gold, crisp focus on each strand, scientific finance theme --ar 5:4 --personalize 3kebfev --v 6.1 Job ID: f40101e1-2e2f-4f40-8d57-2144add82b53
Biotech in 2025: Precision medicine, smarter investments, and more emphasis on RWD in clinical trials
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE